1. Home
  2. > Healthcare
  3. > Health Services Market Trends
Myelofibrosis - Epidemiology Forecast - 2032

Myelofibrosis - Epidemiology Forecast - 2032

  • September 2022
  • 110 pages
  • ID: 6321464
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Myelofibrosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, the EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered
• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• Study Period: 2019–2032

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Myelofibrosis Understanding

Myelofibrosis Overview
Myelofibrosis is a rare type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow. The bone marrow cannot make enough healthy blood cells due to increased scar tissue. It is one of the related groups of blood cancers known as “myeloproliferative neoplasms (MPNs)” in which blood cells produced by bone marrow cells develop and function abnormally. When myelofibrosis develops on its own (and not as the result of another bone marrow disease), it is called primary myelofibrosis. In other cases, another type of MPN, such as polycythemia vera (PV) or essential thrombocythemia (ET), can transform into MF. In these cases, it is known as secondary MF, which may also be referred to as a post-PV MF or post-ET MF.
Myelofibrosis usually develops slowly, and it often does not cause early symptoms and may be found during a routine blood test. When fibrosis develops in the bone marrow, the bone marrow is unable to produce enough normal blood cells. The lack of blood cells causes many signs and symptoms of myelofibrosis. Several specific gene mutations have been identified in people with myelofibrosis. The most common is the Janus kinase 2 (JAK2) gene mutation, and other less common mutations include CALR and MPL. Some people with myelofibrosis do not have any identifiable gene mutations.
Prominent clinical features in myelofibrosis include anemia, hepatosplenomegaly, and constitutional symptoms including fatigue, night sweats, low-grade fever, and progressive cachexia with loss of muscle mass, bone pain, splenic infarct, pruritus, nonhepatosplenic EMH, thrombosis, and bleeding.

Myelofibrosis Diagnosis
Myelofibrosis can be diagnosed by using a series of tests such as blood tests, bone marrow tests, molecular testing, and mutation-enhanced morphologic diagnosis. In order to confirm the diagnosis, the doctor tests the bone marrow. Bone marrow testing involves two steps usually performed at the same time in a doctor’s office or a hospital: a bone marrow aspiration removes a liquid marrow sample, and a bone marrow biopsy removes a small amount of bone filled with marrow. Molecular tests are used for diagnosis and treatment planning look for abnormal changes in the genes, chromosomes, proteins, or other molecules within the patient’s cancer cells.
Epidemiology Perspective
The Myelofibrosis epidemiology division provides insights about the historical and current Myelofibrosis patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Myelofibrosis epidemiology [segmented as total prevalent cases, total diagnosed prevalent cases, type-specific cases, based on risk stratification, age-specific cases, based on molecular alterations, treatment eligible pool of myelofibrosis, and transplant eligible/ineligible pool of myelofibrosis] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Country Wise- Myelofibrosis Epidemiology
? The total prevalent population of myelofibrosis in the 7MM comprised of 39,735 cases in 2021 and is projected to increase during the study period (2019–2032).
? In the United States, the total number of prevalent cases of Myelofibrosis were 19,815 cases in the year 2021 which are expected to grow during the study period, i.e., 2019–2032.
? Among the EU-5 countries, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the UK, whereas Spain accounted for the lowest cases in 2021.
? The total diagnosed prevalent cases of myelofibrosis in the Japan is 5,391 in 2021 and is projected to increase during the forecast period.
? In the US, based on risk, myelofibrosis cases are stratified in the low risk, intermediate-1 risk, intermediate-2, and high-risk. The high-risk accounted for the highest number of patients in 2021 in the US.
? Myelofibrosis can be further categorized into primary myelofibrosis and secondary myelofibrosis. In 2021, primary myelofibrosis accounted for 75% of all cases in the US.
? In the US, based on age, myelofibrosis cases are stratified in the age group ? 40 years, 41?60 years, and > 60 years. The >60 years accounted for the highest number of patients i.e. 10,275 in 2021 in the US.
? In 2021, treatment eligible pool of myelofibrosis accounted for 9,511 cases in the United States.
? The epidemiology model of myelofibrosis suggests that there are two broad classification based on the molecular enhancement in myelofibrosis, one that includes patients who driver harbor mutations which suggests that highest mutation is observed in JAK2 mutations followed by CALR mutation and MLR mutation. Second category includes patients with triple negative mutations. In the US, JAK2 mutations account for approximately 60% of cases.
? In 2021, transplant ineligible pool of myelofibrosis accounted for 8,980 cases in the United States.

Scope of the Report
• The Myelofibrosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Myelofibrosis Report and Model provide an overview of the risk factors and global trends of Myelofibrosis in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom and Japan)
• The report provides insight about the historical and forecasted patient pool of Myelofibrosis in seven major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Myelofibrosis.
• The report provides the segmentation of the Myelofibrosis epidemiology by total prevalent cases, diagnosed prevalent in the 7MM.
• The report provides the segmentation of the Myelofibrosis epidemiology by age-specific, type-specific cases in the 7MM.
• The report provides the segmentation of the Myelofibrosis epidemiology based on the risk stratification and based on molecular alterations in the 7MM.
• The report provides the segmentation of the Myelofibrosis epidemiology by total treated cases and transplant eligible/ineligible cases in the 7MM.

Report Highlights

• 11-Year Forecast of Myelofibrosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Myelofibrosis
• Total Diagnosed Prevalent Cases of Myelofibrosis
• Total Type-specific Cases of Myelofibrosis
• Total Age-specific Cases of Myelofibrosis
• Myelofibrosis Cases Based on Risk Stratification
• Myelofibrosis Cases Based on molecular alterations
• Total Treated Cases of Myelofibrosis
• Total Transplant Eligible/Ineligible Cases of Myelofibrosis
KOL-Views
We interview KOL’s and SMEs ’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
? What is the historical Myelofibrosis patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
? What would be the forecasted patient pool of Myelofibrosis in the 7 major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
? What will be the growth opportunities in the 7MM concerning the patient population about Myelofibrosis?
? Out of all the 7MM countries, which country would have the highest prevalent population of Myelofibrosis during the study period (2019–2032)?
? Which mutation and age-group accounts for the highest prevalent population of Myelofibrosis during the study period (2019–2032) and stratification of myelofibrosis patient pool based on the risk.
? What is the treatment eligible pool of myelofibrosis in the 7MM and the transplant eligible/ineligible pool of myelofibrosis in the 7MM?
? At what CAGR the population is expected to grow in the 7MM during the study period (2019–2032)?
? What are the various recent and upcoming events which are expected to improve the diagnosis of Myelofibrosis?

Reasons to buy
The Myelofibrosis Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Myelofibrosis market
• Quantify patient populations in the global Myelofibrosis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Myelofibrosis therapeutics in each of the markets covered
• Understand the magnitude of the Myelofibrosis population by its severity
• The Myelofibrosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Myelofibrosis Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032

  • $ 3950
  • August 2022
  • 109 pages

‘Idiopathic Pulmonary Fibrosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis historical and forecasted epidemiology as well as the Idiopathic ...

  • Spain
  • Germany
  • Epidemiology
  • Respiratory Disease
  • Industry analysis
  • Health Provider Density

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on